- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Orchestra BioMed targets completed BACKBEAT enrollment by end of Q3 2026 | - | MassDevice | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | 481 | GlobeNewswire (Europe) | Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking... ► Artikel lesen | |
| 12.05. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Orchestra BioMed targets Q3 2026 enrollment for hypertension trial | 3 | Investing.com | ||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 | 240 | GlobeNewswire (Europe) | Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE: MDT, "Medtronic"), the Company's... ► Artikel lesen | |
| 06.05. | Orchestra Biomed picks up $35M from Medtronic, Ligand | 15 | MassDevice | ||
| 06.05. | Medtronic investiert 20 Millionen US-Dollar in Orchestra BioMed | 43 | Investing.com Deutsch | ||
| 06.05. | Orchestra BioMed receives $15 million from Ligand financing deal | 1 | Investing.com | ||
| 06.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | 435 | GlobeNewswire (Europe) | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| 30.04. | Orchestra BioMed wins FDA breakthrough nod for pacemaker in hypertension | - | MassDevice | ||
| 23.04. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 | 1 | GlobeNewswire (USA) | ||
| 26.03. | Jefferies senkt Kursziel für Orchestra BioMed wegen Finanzierungskosten | 2 | Investing.com Deutsch | ||
| 26.03. | Jefferies cuts Orchestra BioMed stock price target on financing costs | 1 | Investing.com | ||
| 12.03. | Chardan reiterates Orchestra BioMed stock rating on trial focus | 2 | Investing.com | ||
| 12.03. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update | 787 | GlobeNewswire (Europe) | $106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics'... ► Artikel lesen | |
| 12.03. | Orchestra BioMed Holdings, Inc. - 10-K, Annual Report | 5 | SEC Filings | ||
| 03.03. | Orchestra BioMed to present hypertension therapy data at medical meetings | 3 | Investing.com | ||
| 03.03. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT | 1 | GlobeNewswire (USA) | ||
| 13.02. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 31,765 | -0,67 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 42,880 | -7,05 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TANGO THERAPEUTICS | 32,640 | +5,43 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,305 | +2,18 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| APOGEE THERAPEUTICS | 87,04 | -1,46 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ABSCI | 7,245 | +6,47 % | Guggenheim hebt Kursziel für Absci auf 15 US-Dollar an - Potenzial durch Haarwuchsmittel | ||
| PRAXIS PRECISION MEDICINES | 264,65 | -0,91 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,255 | +3,17 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 15,330 | +5,00 % | H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights | ||
| IMMUNOVANT | 33,360 | -0,77 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,630 | -0,70 % | H.C. Wainwright cuts Structure Therapeutics stock price target to $70 | ||
| ERASCA | 14,070 | +0,29 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,680 | +5,72 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 23,610 | +0,08 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) | ||
| COGENT BIOSCIENCES | 33,490 | +1,24 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen |
ORCHESTRA BIOMED HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,980 Euro und damit -2,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.